The effect of the phosphodiesterase inhibitor isobutyl-methylxanthine (IBMX), salbutamol and sodium nitroprusside was evaluated regarding PGF-.2 and LTB4 release and cAMP and cGMP level in human alveolar macrophages obtained from controls and COPD patients. Basal levels per five million control-respectively COPD alveolar macrophages: cAMP 1.2 and 1.0 pmole; cGMP 8.4 and 9.1 fmole; PGE. 2 120 and 63 pg and LTB 4 19.2 and 14.8 pg. In both populations IBMX increased cAMP level by 55-93% and salbutamol+IBMX by 285-252%. Except for the 61% rise in LTB, release by salbutamol+lBMX the drugs hardly affected PGE 2 and LTB 4 release from control macrophages. In COPD alveolar macrophages, however, IBMX and IBMX+salbutamol largely reduced PGE 2 release (63 vs 11 pg per l0 s cells) but less efficiently increased LTB 4. In both macrophage populations sodium nitroprusside (SNP) substantially increasod (3-4 fold) cGMP level but did not affect eicosanoid production. Present results indicate that drugs which enhance cAMP level decrease PGF~ release from COPD macrophages and stimulate the release of LTB 4 a chemotactic mediator involved in bronchial inflammatory reactions.
neutrophils (13) . Stimulated AM from asthmatic patients release larger amounts of inflammatory mediators than AM derived from healthy subjects (14, 15) though others did not confirm this (16) . Release of lipid mediators (prostaglandins, leukotrienes and PAF) from AM may have important implications for the micro-environment of the bronchoalveolar compartment.
The modulatory effects of AM depend on various factors like basal intracellular cAMP level, state of priming and exposure to biologically active substances. Increase in intracellular cAMP level generally decreases cellular activity. For instance elevation of cAMP inhibits zymosanstimulated arachidonic acid release in monocytes (17) and the production of thromboxane B2 and LTB 4 in elicited peritoneal macrophages (18) . Whether in addition cGMP level is also of importance in the control of cellular activity is not well established. Zymosan elicits a rapid rise in both cAMP and cGMP formation (19) and muramyl dipeptide (20) , sodium nitroprusside (19) , and exogenous cGMP have been shown to enhance macrophage activity (20, 21) . Others, however, do not observe macrophage activation by inducers of cGMP production (19) .
The effect of bronchodilating drugs (salbutamol, sodium nitroprusside and theophylline-like compounds) are believed to be beneficial only. However, by changing intracellular cyclic nucleotide levels these drugs may in addition alter the functional activity of AM, known to be involved in airway inflammation.
Materials and Methods
Ten patients (female, age 25-40 yrs, mean age 31, all smokers, > 7 pack years) hospitalised for obstetric purposes were studied. None of these subjects had a history of pulmonary disorders or received any medication two months prior to the study. Informed consent for bronchoalveolar lavage (BAL) was obtained. Alveolar cells were obtained by BAL under general anaesthesia using a fiberoptic bronchoscope. BAL fluids containing a total of 25-85 .106 cells were subsequently kept on ice.
Lung tissue was obtained from 8 smoking (> 10 pack years) COPD patients with peripheral carcinoma (6 male, 2 female, mean age 51 years) who had undergone thoracotomy. According to the criteria of the American Thoracic Society all patients were diagnosed for COPD. Patients receiving beta-sympathomimetics or theophylline were excluded from the study. Mean FEV~ was 65.7%, mean FVC was 87.3% (calculated from normal predicted value). Within 30 min after surgical resection tissue was immersed in ice-cold buffer. AM were recovered by in-vitro lavage of segments using a 20 ml syringe. BAL fluids were filtered through surgical gauze and centrifuged at 400g (10 min, 4°C). The pellet was resuspended in Gey Balanced Salt Solution (GBSS), pH 7.4 and AM were purified by Ficoll-Isopaque centrifugation (400g, 30 min, 4°C) and the resultant AM layer was washed twice. May Grtinwald Giemsa staining showed that the suspension contained approximately 96% (control) and 86% (COPD) AM. Viability of the cells was at least 95%. Cells were not further purified via culturing to avoid frustrated phagocytosis eliciting cell activation. AM (2.10 ~ ml "1) were incubated in GBSS buffer at 370C for 60 min and drugs dissolved in GBSS. In some experiments cell suspensions were pre-incubated for 15 min with 10 laM propranolol. Incubation was stopped by centrifugation (1 min, 15,000g) and the supernatant was removed, freeze dried and stored at -80*C for analysis of eicosanoids. The pellet was resuspended in 150 lal Tris-HCl buffer (pH 7.4) and boiled for 3 min. PGE 2 and LTB 4 were assayed by ELISA. Detection limits for PGE 2 and LTB 4 were 3 and 1 pg/ml. Cellular cyclic 
Results

Cellular composition of BAL and basal values of control macrophages
Despite the use of different techniques to harvest broncholaveolar cells, cellular composition may be compared (24) . Analysis of the cellular composition of BAL fluids showed large differences between controls and COPD subjects. BAL fluids of controls contained mainly AM (95%) and some lymphocytes (3.6%). In BAL fluids obtained from COPD patients considerable numbers of eosinophils (7.4%), neutrophils (14.4%) and lymphocytes (10.6%) were present.
Basal values and effects of drugs on cyclic nucleotide levels and eicosanoid release in control AM are denoted in Table 1 . In controls, basal cAMP and cGMP level per 106 AM was 1.4 pmole and 8.4 fmole, reflecting a 160-fold difference in concentration.
Levels of cyclic nucleotides and eicosanoid release in control macrophages
In the presence of the nonselective phosphodiesterase inhibitor IBMX cAMP and cGMP levels rose to respectively 193% and 155% of basal level (cf. The combination of IBMX with the selective betaz-sympathomimetic salbutamol enhanced intracellular cAMP level more efficiently than IBMX alone (185% increase), but compared to IBMX PGF_q release was hardly further inhibited. Considering LTB4 release, however, salbutamoI+IBMX was some two-fold more effective than IBMX alone (30.4 vs 24.2). Propranolol (10 p_M) completely blocked the salbutamol effects (not shown). Sodium nitroprusside (SNP) substantially increases cellular cGMP concentration (additional 134%) but does not affect cAMP content or eicosanoid release. Table 2 shows that untreated AM from COPD patients (refered as COPD-AM) contained less cAMP (-29%) and released considerable less PGF_, 2 and LTB 4 compared to control AM (50% respectively 70%). The drugs IBMX and salbutamol enhanced cyclic nucleotide levels roughly to the same extent as in control AM. However, compared to control AM the reduction in PGE 2 release was much larger (83% vs 21%) while LTB 4 release was slightly enhanced (24%). Salbutamol induced in COPD-AM a further increase in cAMP level (additional +102% compared to IBMX) which was not related to additional changes in PGE 2-or LTB 4 release. SNP showed similar responses in COPD-AM and control AM.
Levels of cyclic nucleotides and eicosanoid release in AM from COPD patients
Discussion
Considering basal values for cAMP and eicosanoid release some interesting differences between the macrophage populations of controls and COPD patients are observed. Others observe about 50-fold lower amounts of eicosanoid released which may be due to the purification technique used (adherence/culturing) enhancing 'basal' activation state due to frustated phagocytosis (25) . In this process eicosanoid release rises, peaks, exhausts and returns to some resting level. Thus it is conceivable that subsequent exposure induces smaller amounts of released eicosanoids. Different results may also be obtained when the metabolism of a nonendogenous pool of tritiated arachidonic acid is determined.
The present study compares COPD-AM with control AM from patients with no history of Vol. 54, No. 17, 1994 cAMP Modulates Eicosanoid Release 1273 pulmonary disorder. Both groups of AM were obtained from smokers only to allow good comparison as it is generally known that smoking impairs certain AM functions including eicosanoid production (26) . In contrast to control-AM, COPD-AM are recovered from patients with a pulmonary environment characterized by frequent unspecified inflammations (note the considerable number of inflammatory cells in the BAL of COPD patients). In addition, COPD-AM are obtained from a rather heterogeneous group of COPD patients consuming a variety of drugs. So COPD-AM differ predominantly from control-AM by their origine from an inflammatory environment which probably renders COPD-AM more elicited than control-AM.
Compared to control-AM, COPD-AM show significantly lower basal level in cAMP and PGE2-and LTB 4 release and behave quite differently regarding induced eicosanoid release. Peritoneal macrophages obtained during peritoneal inflammation likewise showed lower basal cAMP level and PG~ release compared to macrophages collected from patients without such complications (27) . Drug-induced increases in cellular cAMP level was related to decreased PGE 2 and a slight increase in LTB 4 release. These results are only partly comparable with previous results obtained in activated (elicited, cultured or primed) macrophages showing that elevation of cAMP level inhibited both PG~ and LTB 4 release (e.g. 18).
Interestingly, IBMX induces in the two AM populations a similar increase in cAMP level but affects PGE,2 release in COPD-AM to a much larger extent compared to control AM (decrease respectively 83 and 17%). Both macrophage populations show, however, a comparable increase in LTB 4 release in response to IBMX.
We suggest that in control AM the reduction of free arachidonic acid metabolism to PGE2 results in a higher availability of the common substrate (free arachidonic acid) for lenkotriene synthesis by 5-1ipoxygenase. Simultaneous down-regulation of cyclooxygenase and enhanced 5-lipoxygenase activity has recently been observed by Mackenzie et al. (25) in macrophages exposed to calcium ionophore. The suggested inhibition of phospholipase A 2 and release of arachidonic acid from phospholipids by elevated cAMP (28) may only explain the decrease in PGE 2 release but not the change in LTB4 release.
In both control AM and COPD-AM enhancement of cGMP level is not related to either PGE2 or LTB4 release indicating that the cytosolic pool of cGMP is not involved in the regulation of eicosanoid release from AM.
Due to their bronchodilating proporties the xanthine derivative theophylline and beta2-sympathomimetics are frequently used in the treatment of asthma and COPD. Present results indicate that these drugs in addition modulate eicosanoid release from AM which may have important implications for the micro-environment in bronchoalveolar compartment.
